Showing 7751-7760 of 10545 results for "".
- Rosacea Hinders Social Experiences For More Than 16 Million Americanshttps://practicaldermatology.com/news/20130409-rosacea_hinders_social_experiences_for_more_than_16_million_americans/2459570/Roughly half of rosacea patients refuse certain foods and drinks for fear of triggering a rosacea flare-up. That's according to numbers from the National Rosacea Society (NRS), which designated the month of April as Rosacea Awareness Month to alert the public to the early warning signs of rosacea. T
- Novan Therapeutics: Nitric Oxide May Inhibit Skin Steroidogenesis Locallyhttps://practicaldermatology.com/news/20130408-novan_therapeutics_nitric_oxide_may_inhibit_skin_steroidogenesis_locally/2459571/Novan Therapeutics reports topical nitric oxide-based therapies may reduce androgen levels in the skin by locally inhibiting skin steroidogenesis. The targeted reduction of androgens in the skin could lead to first-in-class local antiandrogen products to treat acne and androgenic alopecia (male patt
- New Survey Finds Social Media is a Major Influence on Elective Surgeryhttps://practicaldermatology.com/news/20130327-new_survey_finds_social_media_is_a_major_influence_on_elective_surgery/2459578/Social media is leading consumers to have a more self-critical eye, according to a new survey by the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS). The annual poll of the organization's board-certified facial plastic surgeons found a 31 percent increase in requests for surge
- La Roche-Posay and WDS Expand Sun Protection Campaignhttps://practicaldermatology.com/news/20130320-la_roche-posay_and_wds_expand_sun_protection_campaign/2459583/La Roche-Posay and the Women's Dermatologic Society (WDS) are taking their Time Out, Protect Your Skin (TOPS) initiative national. Launching this year in five public and private schools across the country, the TOPS program will increase awareness about sun protection and instill good skin health hab
- District Court Judge Blocks Marketing and Sales of RevitaLashhttps://practicaldermatology.com/news/20130320-district_court_judge_blocks_marketing_and_sales_of_revitalash/2459584/A district court judge recently prohibited Athena Cosmetics, Inc. from marketing or selling its RevitaLash Advanced Eyelash Conditioner in the United States. The ruling came as part of a civil lawsuit brought by Allergan Inc., maker of Latisse, in which the company claimed unfair competition in the
- On Match Day, AMA Calls for Additional Residency Positions to Address Physician Shortagehttps://practicaldermatology.com/news/20130319-on_match_day_ama_calls_for_additional_residency_positions_to_address_physician_shortage/2459585/A statement released by Jeremy A. Lazarus, M.D., President of the American Medical Association, is seeking to raise awareness about the physician shortage. "Today, on Match Day, thousands of medical students will learn where they will complete their graduate medical education (GME), known as reside
- SkinMedica Unveils Hydroquinone-Free Skin Brightening Complexhttps://practicaldermatology.com/news/20130314-skinmedica_unveils_hydroquinone-free_skin_brightening_complex/2459588/SkinMedica introduced its new skin brightening product, SkinMedica Lytera™ Skin Brightening Complex, a hydroquinone-free product that reduces the appearance of skin discoloration and dark spots. Featuring a proprietary blend of ingredients, SkinMedica Lytera™ Skin Brightening Complex works to bright
- Envy Medical Unveils New Acne Systemhttps://practicaldermatology.com/news/20130311-envy_medical_unveils_new_acne_system/2459595/Envy Medical Inc. recently launched the ClarityMD Acne Solution at the American Academy of Dermatology Annual Meeting on March 1 in Miami. The system includes a Deep Pore Cleanser and Clarifying Gel in a two-step system that's clinically proven to significantly heal acne within days, according to th
- Investigational Injectable Found Safe, Effective for Submental Fathttps://practicaldermatology.com/news/20130311-investigational_injectable_found_safe_effective_for_submental_fat/2459596/An investigational injectable drug for the reduction of submental fat called ATX-101 from Kythera Biopharmaceuticals was found both safe and effective in new data presented at the AAD Meeting in Miami. In the open-label Phase IIIb study, interim results three months after the last ATX-101 treatment
- Apremilast Phase III Results Show Efficacy Over Time for Psoriasishttps://practicaldermatology.com/news/20130311-apremilast_phase_iii_results_show_efficacy_over_time_for_psoriasis/2459597/Results from a new Phase III study presented at the AAD Meeting in Miami demonstrate the efficacy of the oral molecule apremilast (Celgene) in psoriasis patients. The ESTEEM 1 study evaluated efficacy and safety in a range of patients, approximately one-third of which was systemic and/or phototherap